“Lack of evidence” to support cannabinoids as mental health treatment
Researchers looked at the impact of medicinal cannabinoids on depression, anxiety, ADHD, Tourette’s, PTSD and psychosis.
Published: 29th October, 2019 at 12:36
- Share on Facebook
- Share on Twitter
- Share on Whatsapp
- Share on Reddit
- Email to a friend
There is inadequate evidence that cannabinoids relieve depression, anxiety disorders or attention-deficit hyperactivity disorder, scientists have said.
The meta-analysis also looked at the impact of medicinal cannabinoids on Tourette’s syndrome, post-traumatic stress disorder and psychosis.
Research which combined 83 studies involving 3,000 people suggested their use for the 6 mental health conditions cannot be justified based on the current evidence.
Scientists said this is due to a lack of evidence for their effectiveness, and because of the known risks of cannabinoids.
But the study, published in the Lancet Psychiatry journal, suggests there is very low quality evidence that pharmaceutical tetrahydrocannabinol (THC) may lead to a small improvement in symptoms of anxiety in individuals with other medical conditions.
Lead author Professor Louisa Degenhardt, of the National Drug and Alcohol Research Centre (NDARC) at UNSW Sydney, Australia, said: “Our findings have important implications in countries where cannabis and cannabinoids are being made available for medical use.
“There is a notable absence of high-quality evidence to properly assess the effectiveness and safety of medicinal cannabinoids compared with placebo, and until evidence from randomised controlled trials is available, clinical guidelines cannot be drawn up around their use in mental health disorders.”
Medicinal cannabinoids include medicinal cannabis and pharmaceutical cannabinoids, and their synthetic derivatives, THC and cannabidiol (CBD).
Read more about medicinal cannabinoids:
They are increasingly being made available for medicinal purposes in countries like the United States, Australia and Canada, including for the treatment of mental health disorders.
However, researchers say there are concerns around the adverse effects of this availability. This, they say, is due to a large body of evidence indicating that non-medicinal cannabis use can increase the occurrence of depression, anxiety, and psychotic symptoms.
The authors analysed published and unpublished studies between 1980 and 2018. Of the 83 eligible studies, 40 were randomised controlled trials (RCTs), and the others were open-label trials, where participants knew which treatment they were taking.
42 of the 83 studies looked at depression (including 23 RCTs), 31 looked at anxiety (17 RCTs), 8 looked at Tourette’s syndrome (2 RCTs), 3 were on ADHD (one RCT), 12 were on PTSD (one RCT), and 11 were on psychosis (6 RCTs).
In most RCTs examining depression and anxiety, the primary reason for cannabinoid use was for another medical condition such as chronic non-cancer pain or multiple sclerosis.
The cannabinoid was used to treat the mental health disorder in the studies that looked at the other 4 disorders.
What is CBD oil?
The cannabis plant, Cannabis sativa, contains a number of active ingredients, including THC and CBD. THC (tetrahydrocannabinol), the most active ingredient of marijuana, is the component that makes a person high when either smoked or ingested. Cannabidiol (CBD), on the other hand, is not psychoactive: it doesn’t induce a mind-altering effect.
CBD oil is a way of delivering CBD. This chemical is first extracted from the plant and then diluted with a carrier oil like hemp seed. It can then be consumed as either the oil itself or within drinks or confectionary. In the UK, it can be found in health shops.
Only a few RCTs looked at the role of pharmaceutical CBD or medicinal cannabis – most looked at THC, with or without CBD.
Researchers found pharmaceutical THC (with or without CBD) improved anxiety symptoms among individuals with other medical conditions.
However, this may have been due to improvements in the primary medical condition.
The authors suggest further research should study the effects of cannabinoids on anxiety and depression.
According to the analysis, pharmaceutical THC – with or without CBD – worsened negative symptoms of psychosis in one study of 24 people, and did not significantly affect any other primary outcomes for the mental health disorders examined.
It also increased the number of people who had adverse events and withdrawals due to adverse events, compared with placebo across all mental health disorders examined.
Read more mental health stories:
Scientists say there is a need for high-quality research to understand the effects of different cannabinoids on a range of outcomes for people with mental health disorders.
They highlight that their analysis and conclusions are limited by the small amount of available data, small study sizes, and the differences in findings between small studies.
“The Lancet Psychiatry meta-analysis rather misses the point,” commented Professor David Nutt, Head of the Centre for Neuropsychopharmacology at Imperial College London.
“Cannabis has been a medicine for millennia, with governments and regulators more recently expanding access through a variety of mechanisms, so subjecting it to the same requirements as modern synthetic medicines is not the most obvious nor necessary way to progress.
“Unfortunately in the UK this self-treatment is largely with black market cannabis of unknown strength and provenance, and is potentially associated with significant public health harms.”
Experimental Medicine in ADHD – Cannabinoids (EMA-C)
Adult patients with ADHD commonly report an improvement in behavioural symptoms when using cannabis with some reporting a preference towards cannabis over their ADHD stimulant medication. The EMA-C study aims to investigate the effects of a cannabis based medication, Sativex Oromucosal Spray on behaviour and cognition in adults with ADHD.
This will be carried out by conducting a placebo controlled trial. 30 adults with ADHD will take Sativex or a dummy medication (a placebo) every day for 6 weeks. There is a 50% chance of receiving the Sativex or Placebo. Measures of behaviour and cognition will be taken before and after 6 weeks of treatment. We hypothesise that treatment with Sativex will result in improvements in behaviour and cognition above that of the placebo group.